Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinamide Riboside in MCI and Mild AD
NCT04430517Phase 1Completed
- Sponsor
- McLean Hospital
- Start
- Mar 2022
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nicotinamide riboside in Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD), sponsored by McLean Hospital. Primary endpoints: Changes in brain NAD+ at 12 weeks and Changes in brain redox state at 12 weeks. Started Mar 2022; status: completed.
02
Drugs
nicotinamide riboside
03
Conditions
Mild Cognitive Impairment (MCI)Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04430517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04430517.